UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Rule 13d-102)
Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Reva Medical, Inc.
(Name of Issuer)
Common Stock, Par Value $.0001
(Title of Class of Securities)
76133E109
(CUSIP Number)
December 31, 2014
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to
which this schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form
with respect to the subject class of securities, and for any subsequent
amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the
liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the
Notes).
CUSIP No. 76133E109
13G/A
Page 2 of 8 Pages
1.
NAME OF REPORTING PERSON
Brookside Capital Partners Fund, L.P.
2.
(a) 0
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(b) 0
3.
SEC USE ONLY
4.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.
SOLE VOTING POWER
2,783,204 Shares
6.
SHARED VOTING POWER
0
7.
SOLE DISPOSITIVE POWER
2,783,204 Shares
8.
SHARED DISPOSITIVE POWER
0
9.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,783,204 Shares
10.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
11.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
8.30%
12.
TYPE OF REPORTING PERSON
PN
CUSIP No. 76133E109
13G/A
Page 3 of 8 Pages
13.
NAME OF REPORTING PERSON
Brookside Capital Trading Fund, L.P.
14.
(a) 0
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(b) 0
15.
SEC USE ONLY
16.
CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
17.
SOLE VOTING POWER
181,818 Shares
18.
SHARED VOTING POWER
0
19.
SOLE DISPOSITIVE POWER
181,818 Shares
20.
SHARED DISPOSITIVE POWER
0
21.
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
181,818 Shares
22.
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES
23.
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.54%
24.
TYPE OF REPORTING PERSON
PN
Item 1(a). Name of Issuer
The name of the issuer to which this filing on Schedule 13G/A
relates is Reva Medical, Inc. (the
"Company").
Item 1(b). Address of Issuer's Principal Executive Offices
The principal executive offices of the Company are located at
5751 Copley Drive, San Diego, CA
92111.
Item 2(a). Name of Person Filing
This Statement is being filed on behalf of the following
(collectively, the "Reporting Persons"):
(1) Brookside Capital Partners Fund, L.P., a Delaware limited partnership
("Partners Fund"). Brookside
Capital Investors, L.P., a Delaware limited partnership
("Brookside Investors") is the sole general partner
of the Brookside Fund. Brookside Capital Management, LLC, a Delaware
limited liability company
("Brookside Management"), is the sole general partner of
Brookside Investors. (2) Brookside Capital
Trading Fund, L.P., a Delaware limited partnership (the "Brookside Fund").
Brookside Capital Investors
II, L.P., a Delaware limited partnership ("Brookside Investors II")
is the sole general partner of the
Brookside Fund. Brookside Management is the sole general partner of
Brookside Investors II.
The Reporting Persons have entered into a Joint Filing Agreement,
dated February 17, 2015, a
copy of which is filed with this Schedule 13G/A as Exhibit A, pursuant
to which the Reporting Persons
have agreed to file this statement jointly in accordance with the
provisions of Rule 13d- 1(k)(1) under the
Securities Exchange Act of 1934.
Item 2(b). Address of Principal Business Office or, if none,
Residence
The principal business address of each of the Partners Fund,
Brookside Fund, Brookside
Investors, Brookside Investors II, Brookside Management is c/o John
Hancock Tower, 200 Clarendon
Street, Boston, MA 02116.
Item 2(c). Citizenship
Each of the Partners Fund, Brookside Fund, Brookside Investors,
Brookside Investors II, and
Brookside Management is organized under the laws of the State of
Delaware.
Item 2(d). Title of Class of Securities
The class of equity securities of the Company to which this
filing on Schedule 13G/A relates is
Common Stock, Par Value $.0001 ("Common Stock").
Item 2(e). CUSIP Number
The CUSIP number of the Company's Common Stock is 76133E109.
Item 3. If this statement is filed pursuant to 240.13d-1(b) or
240.13d-2(b) or (c), check
whether the person filing is a:
(a) [ ] Broker or dealer registered under section 15 of the
Act (15 U.S.C. 78o).
(b) [ ] Bank as defined in section 3(a)(6) of the Act
(15 U.S.C. 73c).
(c) [ ] Insurance company as defined in section 3(a)(19) of the
Act (15 U.S.C. 78c).
(d) [ ] Investment company registered under section 8 of the
Investment Company Act of 1940 (15
U.S.C. 80a-8).
(e) [ ] An investment adviser in accordance with
13d-1(b)(1)(ii)(E).
(f) [ ] An employee benefit plan or endowment fund in
accordance with 240.13d-1(b)(1)(ii)(F).
(g) [ ] A parent holding company or control person in
accordance with 240.13d-1(b)(1)(ii)(G).
(h) [ ] A savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act (12
U.S.C. 1813).
(i) [ ] A church plan that is excluded from the definition
of an investment company under section
3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
(j) [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(J).
[x] If this statement is filed pursuant to 240.13d-1(c),
check this box.
Item 4. Ownership
Item 4(a). Amount beneficially owned
As of the close of business on December 31, 2013, the following
shares were held by the
Reporting Persons:
Partners Fund held 2,783,204 shares of Common Stock,
representing 8.30% of the Company's
outstanding shares of Common Stock.
Trading Fund held 181,818 shares of Common Stock, representing
0.54 % of the Company's
outstanding shares of Common Stock.
As a result of the foregoing and the relationships described
in Item 2(a), the Reporting Persons
may be deemed to beneficially own in the aggregate 2,965,022 shares
of Common Stock of the Company,
representing, in the aggregate, 8.84% of the Company's outstanding
shares of Common Stock. The
percentage of the Company's outstanding shares of Common Stock held
by the Reporting Persons is
based on 33,529,778 shares of Common Stock outstanding as of
November 6, 2014, as reported in the
Company's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on
November 6, 2014.
Item 4(b). Percent of Class
See Item 4(a) hereof.
Item 4(c). Number of shares as to which such person has:
(i) sole power to vote or to direct the vote: 2,965,022 Shares
(ii) shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the
disposition of: 2,965,022 Shares
(iv) shared power to dispose or to direct the
disposition of: 0
Item 5. Ownership of Five Percent or Less of a Class
Not Applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not Applicable.
Item 7. Identification and Classification of the Subsidiary which
Acquired the Security Being
Reported on by the Parent Holding Company:
Not Applicable.
Item 8. Identification and Classification of Members of the Group
Not Applicable.
Item 9. Notice of Dissolution of Group
Not Applicable.
Item 10. Certification
By signing below, the undersigned certifies that, to the best
of its knowledge and belief, the
securities referred to above were not acquired and are not held for
the purpose of or with the effect of
changing or influencing the control of the issuer of the securities
and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.
Dated: February 17, 2015
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information
set forth in this statement is true, complete, and correct.
BROOKSIDE CAPITAL PARTNERS FUND, L.P.
By: Brookside Capital Investors, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner
By: /s/ William E. Pappendick IV
Name: William E. Pappendick IV
Title: Managing Director
BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner
By: /s/ William E. Pappendick IV
Name: William E. Pappendick IV
Title: Managing Director
Exhibit A
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G/A
The undersigned hereby agree as follows:
(1) Each of them is individually eligible to use the Schedule
13G/A to which this Exhibit is attached,
and such Schedule 13G/A is filed on behalf of each of them; and
(2) Each of them is responsible for the timely filing of such
Schedule 13G/A and any amendments
thereto, and for the completeness and accuracy of such information
concerning such person
contained therein; but none of them is responsible for the completeness
or accuracy of the
information concerning the other persons making this filing, unless
such person knows or has
reason to believe that such information is inaccurate.
Dated: February 17, 2015
BROOKSIDE CAPITAL PARTNERS FUND, L.P.
By: Brookside Capital Investors, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner
By: /s/ William E. Pappendick IV
Name: William E. Pappendick IV
Title: Managing Director
BROOKSIDE CAPITAL TRADING FUND, L.P.
By: Brookside Capital Investors II, L.P.,
its general partner
By: Brookside Capital Management, LLC,
its general partner
By: /s/ William E. Pappendick IV
Name: William E. Pappendick IV
Title: Managing Director